Skip to main content

Table 2 Selected PICOT questions

From: Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

Question

Influence of adherence to ICS therapy on asthma outcomes

Influence of device type for ICS therapy on asthma outcomes

Influence of smoking on asthma outcomes in patients receiving ICS therapy

Influence of ICS particle size on asthma outcomes

Population

Asthmatics of all ages prescribed regular maintenance ICS

Asthmatics of all ages prescribed regular maintenance ICS

Asthmatics of all ages prescribed regular maintenance ICS

Asthmatics of all ages prescribed regular maintenance ICS

Intervention

Adherence to recommended therapy

Different inhaler devices/delivery systems

Smokers

Extra-fine particles ICS

Comparison

Different levels of adherence (e.g. 0–25%, 25–50%, 50–75%, over 75%)

Different inhaler systems (pMDI, breath-activated MDI, DPI) for delivering the same molecule

Ex/non-smokers

Fine particles ICS

Outcomes

Exacerbations, admissions, symptoms, QOL

Exacerbations, admissions, symptoms, QOL

Exacerbations, admissions, symptoms, QOL

Exacerbations, admissions, symptoms, QOL

Time frame

≥ 12 months

≥ 12 months

≥ 12 months

≥ 12 months